Moda-flx Hemodialysis System™ Under Professional Care Settings by Trained Individuals and At Home by Participants

Last updated: November 5, 2025
Sponsor: Diality Inc.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Kidney Failure (Pediatric)

Nephropathy

Renal Failure

Treatment

Moda-flx Hemodialysis System™

Clinical Study ID

NCT06613568
DIA-HHD-001
  • Ages 18-80
  • All Genders

Study Summary

The purpose of this study is to evaluate the safety and efficacy of the Moda-flx Hemodialysis System™ when used Under Professional Care Settings by trained individuals and At Home by trained Participants and Care Partners

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Are between 18 and 80 years of age and Care Partner is at least 18 years of age atthe time of signing consent.

  • Have a diagnosis of end stage kidney disease (ESKD) adequately treated bymaintenance dialysis (defined as achieving a spKt/V ≥ 1.2 OR stdKt/V ≥ 2.1) and bedeemed stable by their treating nephrologist prior to the end of the ScreeningPeriod

  • Have a well-functioning and stable vascular access (tunneled central venous catheterarteriovenous fistula, or graft) that allows a blood flow of at least 300 ml/minprior to the end of Screening

  • Can successfully complete a Skills and Comprehension Assessment with a Care Partnerprior to the completion of the Training Period.

Exclusion

Exclusion Criteria:

  • Hgb level of < 9 g/dL at Screening

  • Symptomatic intradialytic hypotension requiring medical intervention (ultrafiltration turned off, bolus of fluid) in at least two treatments during theRun-In period defined as:

  1. Persistent pre-dialysis sitting SBP < 100 mmHg despite medical therapy,

  2. Nadir intradialytic Systolic Blood Pressure (SBP) < 90 mmHg, if Subject'spre-HD SBP < 160 mmHg

  3. Nadir intradialytic SBP < 100 mmHg if Subject's pre-HD SBP ≥ 160 mmHg

  • Documented history of non-adherence to dialysis therapy that would preventsuccessful completion of the study

  • Participant had an average ultrafiltration rate > 13 mL/kg/hour during the last 2weeks prior to Screening, per medical records.

  • Had a significant cardiovascular adverse event within the last 90 days prior toScreening.

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: Moda-flx Hemodialysis System™
Phase:
Study Start date:
October 06, 2025
Estimated Completion Date:
September 30, 2027

Connect with a study center

  • North America Research Institute

    San Dimas 5391891, California 5332921 91773
    United States

    Active - Recruiting

  • Nephrology Associates of Knoxville

    Knoxville 4634946, Tennessee 4662168 37920
    United States

    Active - Recruiting

  • aQua Research Institute, LLC

    Houston 4699066, Texas 4736286 77058
    United States

    Active - Recruiting

  • University of Washington

    Seattle 5809844, Washington 5815135 98104
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.